Recent

% | $
Quotes you view appear here for quick access.

Nanosphere, Inc. (NSPH) Message Board

  • sammyjammin sammyjammin Mar 4, 2011 12:16 PM Flag

    Investigators concluded that a baseline PSA of 3 ng/mL is an appropriate minimum cutoff

    "In a population-based screening study of nearly 20,000 men in Rotterdam, men with baseline prostate-specific antigen (PSA) levels < 3 ng/mL were at very low risk of developing prostate cancer. Investigators concluded that a baseline PSA of 3 ng/mL is an appropriate minimum cutoff for determining the need for biopsy and that longer intervals between PSA screening may be possible in this group.

    The results were presented at the 2011 Genitourinary Cancers Symposium, in Orlando, Florida, by lead investigator Monique Roobol, PhD, an epidemiologist from Erasmus University Medical Center in Rotterdam (Bul et al, abstract 7). The Rotterdam study is part of the European Randomised Study of Screening for Prostate Cancer (ERSPC), a randomized controlled trial running in eight European countries (Belgium, Finland, France, Italy, The Netherlands, Spain, Sweden, and Switzerland)."

    http://www.cancernetwork.com/prostate-cancer/content/article/10165/1813606?GUID=B6570F3E-2771-4D22-A9CB-AEE9E2F98773&rememberme=1&source=NL

    And all of the current FDA-cleared PSA tests already meet this requirement and ultra-sensitive is not needed.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NSPH
4.14+0.27(+6.89%)12:55 PMEDT